EndoPredict breast cancer testing

  • Provides three separate results to optimize treatment for patients with breast cancer

  • Greater prognostic value compared to first generation tests in both node-negative and node-positive disease1

  • Safely moves more patients to low risk avoiding costly chemotherapy1

Fact Sheets and Product Info:

Photo of woman smiling

Executive Summary

 Download PDF

Photo of woman using lab equipment

Tech Specifications

 View Info

Photo of couple smiling

Clinical Dossier

 Download PDF

Close-up of hands typing on laptop computer

Digital Dossier

 View Dossier

About Breast Cancer:

Breast cancer is the second most common cancer in women after skin cancer. In 2020, it is estimated that there will be 276,480 new cases of female breast cancer and an estimated 42,170 people will die of this disease.2

About EndoPredict:

EndoPredict (EPclin), a breast cancer prognostic test, analyzes RNA expression of 8 target genes, 3 normalization genes, and 1 control gene, creating a 12-gene molecular score, which is then combined with clinical features of the tumor (tumor size and nodal status) to predict the 10-year distant recurrence (DR) rate. This information may be used by treating physicians to guide therapy decisions by identifying which patients have sufficiently low risk of DR and may safely forgo chemotherapy, and which patients are at high risk for DR and may need adjuvant chemotherapy in addition to endocrine therapy.

1. Sestak I, Buus R, Cuzick J, et al. JAMA Oncol. 2018 Feb;4(4):545-553.

2. National Cancer Institute. Retrieved September 2020 from: https://seer.cancer.gov/statfacts/html/breast.html.